

PERSISTENT PARADOXICAL EFFECTS ON STRIATAL AND LIMBIC ALPHA-SYNUCLEIN AND TYROSINE HYDROXYLASE FOLLOWING METHAMPHETAMINE WITHDRAWAL

Francesca Biagioni¹, Cinzia Fabrizi², Elena Pompili², Rosangela Ferese¹, Carla Letizia Busceti¹, Stefano Puglisi-Allegra¹, Francesco Fornai^{1,3}

¹I.R.C.C.S. Neuromed, Pozzilli, Italy;

²Dep. of Anatomy, Histology, Forensic Medicine and Orthopedics, Sapienza University of Rome, Rome, Italy;

³Dep. Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.

Introduction


Methamphetamine (Meth) administration leads to experimental parkinsonism in rodents and primates, while in humans long-lasting Meth intake may increase the risk to develop Parkinson's disease (PD). PD is included in a disease group named synucleinopathies. Methamphetamine (METH) produces a variety of epigenetic effects in the brain, which are seminal to establish long-lasting alterations in neuronal activity. A number of studies were carried out aimed at rough assessment of the amount of either histone acetylation and methylation or direct DNA methylation, without a selective analysis of specific genes. In the present study we wish to assess whether METH-induced epigenetic alterations may specifically engage the expression of α -synuclein, which is a key protein in neurodegeneration and synaptic plasticity. In this way, a potential long-term alteration of brain circuitry may produce a variation in the threshold for neurotoxicity, sensitization, addiction and neurodegeneration. Thus, the occurrence of long-term changes in the expression of the protein were analyzed in parallel with persistent changes in a specific marker of integrity of meso-striatal/meso-limbic pathway, which is the expression of tyrosine hydroxylase (TH) both in the mesencephalon and within dorsal striatum. The integrity of dopamine (DA) projection was assessed at the level of the olfactory tubercle, the *nucleus accumbens* and *fundus striati*. Prolonged exposure to small doses of METH, produces nigro-striatal toxicity, when assessed at short time intervals following prolonged exposure. However, at prolonged time intervals a paradoxical increase progressively occurred in TH immunostaining within limbic regions. Such an increase exceeds at large the amount of TH expressed in controls. This occurs concomitantly with an overexpression of the primary transcript as well as the protein α -synuclein within the same brain regions and dorsal striatum. This increase is persistent at prolonged time interval of METH withdrawal. The increase in the primary α -synuclein transcript is due to hypomethylation of specific CpG islands placed in the SNCA gene promoter which ranged roughly ten-fold of controls, it was steady, and it persisted at least 21 days following METH withdrawal. Thus, such an apparent synucleinopathy induced by METH indeed was associated with increased mesolimbic DA innervation, which equally surpasses several folds the amount which was measured in controls and persists at least for three weeks. The increase in SNCA is not associated with an increase of SNCA copy number. Nonetheless, the amount of the native protein, which is detected by ultrastructural stoichiometry, exceeds the increase reported following genetic SNCA duplications (ten-fold of controls). These findings are discussed in the light of METH-induced phenotype changes which accompany toxicity, sensitization, addiction and neurodegeneration.

Methods

C57 black 6/J, 8 weeks-old male mice (Charles River Calco, Mi, Italy, N=120) we chose based on previous literature and our previous studies in different mouse strains. Methamphetamine administration and experimental design: A total of 120 mice were dedicated to these experiments. A group of 48 mice was dedicated to electron microscopy, while 72 mice were sacrificed for immunohistochemistry, protein assay, and DNA analysis. These latter 72 mice were divided into different experimental groups (N=24 each) according to three experimental protocols. These protocols consisted in different dosing and timing of Meth or saline administration. Methamphetamine (Meth, Sigma Aldrich Saint Louis, MO, U.S.A., Authorization n° SP/096, 05.15.2016, granted by the Italian Ministry of Health, was dissolved in saline and it was injected i.p. in a volume of 200 μ L; saline was administered i.p. at the same volume). In the first subgroup (N=24) mice were sacrificed at different time intervals (1 h, 24 h, 7 d) following the last Meth injection; an additional group of mice (N=6) was administered saline (Controls). Meth was administered at the dose of 5 mg/Kg ($\times 5$, 2 h apart). From now on we refer to this protocol as acute time-course protocol since Meth was administered in a single day with a short-time interval between starting Meth and sacrifice. In the second subgroup of mice (N=24) Meth (5 mg/Kg), was injected daily, for 7 d. These mice were sacrificed at different time intervals (24 h, 7 d, 21 d), after the last administration; an additional group (N=6) was administered saline (Controls). From now on we refer to this protocol as sub-acute time-course protocol ($\times 7$) since Meth was administered for 7 d. The third subgroup of mice (N=24) received Meth (at the dose of 5 mg/Kg) daily, for 21 d and they were sacrificed at different time intervals (24 h, 7 d, 21 d), after the last injection; an additional group (N=6) was administered saline (Controls). This protocol was named chronic time-course protocol ($\times 21$). This corresponds to the most chronic condition since Meth treatment lasted 21 d. In both sub-acute and chronic protocols, the longest withdrawal between the last Meth injection and sacrifice was 21 d, which allows detecting the persistence of the effects induced by Meth. These mice were sacrificed by deep chloral hydrate anesthesia and their brains were quickly removed and processed according to different procedures. Since the critical data were obtained following acute and chronic protocols, further experiments were aimed at analyzing ultrastructural morphology according to both acute and chronic time-course protocols. For these additional experiments we used 48 mice, which were sacrificed according to the acute (N=24) or the chronic (N=24) time-course protocol. **Post-sacrifice brain processing:** In the first experimental block (N=72), after sacrifice, the brains were quickly removed from the skull and they were divided into two hemispheres; one hemisphere was constantly used for immunohistochemical studies, while the other hemisphere was used either for immunoblot analysis, or DNA extraction for SNCA mutation detection, and methylation detection assay within SNCA promoter. In the second experimental block (N=48) mice were perfused trans-cardially under deep chloral hydrate anesthesia. The brains were dissected and immersed at 4 °C, overnight, in the perfusing solution. Tissue blocks from striata at the same level of that used for other assays were post-fixed, and transferred on SDS-polyacrylamide gels (12%) and transferred on Immobilon-P/PVDF membranes (BioRad) for 1 h. Membranes were blocked for 2 h in Tween-20 TBST-buffered saline (TTBS) containing 5% non-fat dry milk. Membranes were incubated overnight at 4 °C with primary antibodies rabbit anti- α -syn (1:1000; Sigma Aldrich), or mouse anti-TH (1:1000; Millipore). Blots of TH and α -syn were assessed for optical density being normalized for β -actin blots (Software: ImageJ) and expressed as the mean \pm S.E.M. **DNA extraction:** The mouse striatal DNA following each experimental protocol (Meth- and saline-treated mice) was extracted by NucleoSpin Tissue (Macherey-Nagel GmbH & Co KG) according to the manufacturer's instructions. The entire SNCA coding sequence (NM_001024511), as well as exon/intron boundaries and flanking intronic regions were analyzed by PCR and direct sequencing. The PCR assay was performed in 25 μ L containing 50 ng genomic DNA (GoTaq® Flexi DNA Polymerase, Promega), PCR mix was amplified using the following cycle: 94 °C for 45 s, 58 °C for 30 s, 72 °C for 45 s ($\times 35$ cycles), followed by a 6 min extension at 72 °C. PCR products were sequenced using ABI BigDye Terminator Sequencing Kit v.3.1 (Applied Biosystems) and ABI 3130 Genetic Analyzer (Applied Biosystems). qPCR was performed in a CFX Connect™ Real Time System (Bio-Rad Life Science) using SYBR Green PCR Master (Applied Biosystems). The relative copy number was calculated through a $\Delta\Delta$ CT method, using β -Globin as an internal reference. qPCR was carried out in triplicate for each sample. Ten μ L SYBR Green PCR Master (Applied Biosystems), 0.5 μ M of each primer and 5 ng of genomic DNA were used as amplification reagents acting in a 15 μ L volume. The PCR reaction took place at 95 °C for 10 min, 95 °C for 30 s, 58 °C for 1 min (40 cycles). The samples were homogenized in a lysis buffer and genomic DNA was sonicated using the S220 AFA Ultrasonicator (Covaris Inc.). The sonicated DNA was immunoprecipitated with a monoclonal antibody against 5-hydroxymethylcytosine (5-hmC) (Diagenode) and it was incubated for 4 h at 4 °C. The DNA-antibody complex was enriched with Dnase I (Life Technologies) and it was digested with Proteinase K. Both DNA fragments in the input and pulled down fractions were purified with phenol-chloroform extraction followed by acetone precipitation. Real-Time PCR was carried out to amplify a region corresponding to CpG island identified within SNCA promoter. Real-Time PCR was amplified in a CFX Connect™ Real Time System (Bio-Rad Life Science) at 95 °C for 10 min, 95 °C for 2 min, 54 °C for 1 min (40 cycles) using the following primers: SNCA, FW-5'-TCCCTAGCTCTGTGAAAGC-3' and RW-5'-CTCCTGCTAGCAGG-3'; GAPDH (as an internal reference) (Diagenode) were used as an internal reference. Percentage of methylation for CpG obtained was expressed by averaging the values of all CpGs per assay (0% non-methylated, 100% fully methylated). 5hmC MeDIP Real-Time PCR data were first normalized using the efficacy of each qPCR assay. The ratio IP/Input was transformed in percentage. **Immunogold-transmission electron microscopy:** Tissue blocks from striata at the same level of that considered for immunostaining and SDS-PAGE immunoblotting were dissected for transmission electron microscopy (TEM). From these blocks, 50 μ m thick sections were cut following a coronal plane. All sections were obtained from blocks previously fixed in a solution containing 2.0% paraformaldehyde and 0.1% glutaraldehyde in 0.1M PBS (pH=7.4) for 90 min at 4 °C. After removing the fixing solution, striatal sections were post-fixed in 1% OsO₄ for 1 h at 4 °C; they were dehydrated in ethanol and finally embedded in epoxy resin. For ultrastructural morphology, grids containing non-serial ultrathin sections (40–50 nm thick) were examined at TEM, at a magnification of 8000 \times . Cells to be counted were carefully selected based on ultrastructural criteria, which were previously described for medium-sized striatal neurons. Plain TEM was implemented by post-embedding immunocytochemistry for antibodies against α -syn. At the end of the plain TEM or immunocytochemistry, ultrathin sections were stained with uranyl acetate and lead citrate, and they were finally examined using a JEOL JEM-100SX TEM (JEOL). Fixing and post-fixing solutions and the use of epoxy resin were validated in our previous studies for immunogold-based ultrastructural morphology. **Statistical analysis:** All data are shown as the mean \pm S.E.M. in each group.


RESULTS

1. Pilot dual alpha-synuclein immunostaining compared with classic tyrosine-hydroxylase immunostaining in the whole striatum.




Slices from Controls (saline-treated mice) at striatal level (AP=+1.10 from Bregma) were stained to show representative images of differential α -syn primary antibody specificity. This pilot study on striatal immunostaining was compared with a currently available BD anti- α -syn antibody (AB_398108; right slice); the left slice reports a classic striatal TH immunostaining (Sigma Aldrich; AB_477560; left slice). Immunostaining with anti- α -syn antibody shows a higher specificity for Sigma compared with BD anti- α -syn antibody. Scale bar 200 μ m.

2. Methamphetamine reduces tyrosine-hydroxylase immunoreactivity in the acute time-course protocol




Immunoblot analysis shows a significant reduction in TH protein levels at 24 h and 7 d after the last Meth administration according to the acute time-course protocol (5 mg/Kg \times 5, 2 h apart). No changes were detected at 1 h (left and right panels) (* p < 0.052 vs. saline alone). Immunohistochemical analysis of TH expression confirm the data obtained from immunoblot analysis. Densitometric analysis ratifies the data obtained in the striatum of Meth-treated animals compared with Controls (saline-treated mice) (** p < 0.0001 vs. saline and Meth 1 h). Scale bar 100 μ m.

3. Meth reduces tyrosine-hydroxylase immunostaining following both sub-acute and chronic time-course protocols




Methamphetamine reduces tyrosine-hydroxylase immunoreactivity in the sub-acute and chronic time-course protocol. Immunoblot analysis demonstrates a significant reduction in TH protein levels in both sub-acute and chronic administration protocols (5 mg/Kg \times 7 or 5 mg/Kg \times 21 d) (p < 0.0001 vs. saline). Immunohistochemistry shows a significant reduction of TH protein levels at 24 h and 7 d, and a partial recovery at 21 d after the last Meth administration according to the sub-acute time-course protocol (p < 0.0001 vs. saline; ** p < 0.0001 vs. saline and Meth 24 h; *** p < 0.0001 vs. saline and Meth 7 d). TH levels were significantly reduced at 24 h after the last Meth administration according to the chronic time-course protocol. At 7 d and 21 d of Meth withdrawal, there is a partial recovery of TH, which in any case, remains significantly lower than Controls (saline-treated mice; ** p < 0.0001 vs. saline; ** p < 0.0001 vs. saline and Meth 24 h). Scale bar 100 μ m.

4. Meth persistently increases striatal alpha-synuclein immunostaining in sub-acute and chronic time-course protocols only




Methamphetamine increases alpha-synuclein immunoreactivity in the acute, sub-acute and chronic time-course protocols. Immunohistochemical analysis shows a remarkable increase of α -syn protein in acute time-course protocol at 1 h after the last administration of Meth. This increase is no longer evident at 24 h and 7 d. When administered according to sub-acute and chronic time-course protocols, Meth significantly increases α -syn immunoreactivity at any time of withdrawal analyzed (5 mg/Kg \times 7 and 5 mg/Kg \times 21). Scale bar 100 μ m.

5. Meth increases alpha-synuclein protein levels and promotes hypomethylation of SNCA promoter in the acute time-course protocol.




Immunoblot analysis demonstrates a significant increase in α -syn protein levels at 1 h. Densitometric analysis was obtained as the mean \pm S.E.M. The figure shows a representative gel of the mean values quantified in the graph as arbitrary units (** p < 0.0001 vs. saline; *** p < 0.0001 vs. saline and Meth 1 h). Hypomethylation of SNCA promoter following acute Meth administration (5 mg/Kg \times 5, 2 h apart). In this experimental condition, significant SNCA hypomethylation was observed only at 1 h of Meth withdrawal, while no changes were observed at 24 h and 7 d (* p = 0.0036; ** p = 0.05 vs. Meth 1 h).

6. Meth increases alpha-synuclein protein levels and promotes hypomethylation of SNCA promoter in the sub-acute and chronic time-course protocol.




Immunoblot analysis demonstrates a significant increase in α -syn protein levels at 7 d which persists at 21 d after the last administration of Meth according to the sub-acute (5 mg/Kg \times 7 d) and chronic time-course protocol (** p < 0.016 vs. saline alone). A consistent hypomethylation of SNCA promoter following a sub-acute and chronic treatment is shown (5 mg/Kg \times 7 d and 5 mg/Kg \times 21 d) (p < 0.0001 vs. saline alone; ** p < 0.0001 vs. saline and Meth 24 h; *** p < 0.0001 vs. Meth 24 h and Meth 7 d; * p < 0.0001 vs. saline alone; ** p < 0.0001 vs. saline and Meth 7 d).

7. Meth persistently increases striatal alpha-synuclein immunostaining in other brain regions




8. A single day of multiple injections transiently alters alpha-synuclein immunogold particles within striatal neurons




Representative micrographs from striatal cells stained for α -syn immunogold particles (10 nm in diameter) from saline- and Meth-treated mice at 1 h, 24 h, and 7 d of withdrawal. Panel A shows a representative cell from a Control (saline-treated) mouse which contains very few cytosolic α -syn immunogold particles (arrows). At 1 h of withdrawal, acute Meth administration (5 mg/Kg \times 5, 2 h apart) robustly increases α -syn particles both in the nucleus and cytoplasm (arrows), as shown in panel B. Instead, at 24 h and 7 d of Meth withdrawal, the amount of α -syn particles (arrows) falls back nearly to control levels (panel C and D, respectively). The graph reports the stoichiometric count of α -syn immunogold particles in striatal cells from Meth-treated mice expressed as a percentage of values obtained from Controls (saline-treated mice). The data indicate that, when Meth is administered according to an acute time-course protocol, it significantly increases α -syn only at short-time intervals (1 h) of withdrawal (** p < 0.05 with respect to saline); N=nucleus; M=mitochondria. Scale bars A, C, D=400 nm; B=200 nm.

9. Chronic Meth administration produces a dramatic and persistent increase in alpha-synuclein immunogold particles



Representative micrographs from striatal cells stained for α -syn immunogold particles (10 nm in diameter) from saline- and Meth-treated mice at 24 h, 7 d, and 21 d of withdrawal. Panel A shows a representative cell from a saline-treated mouse which contains very few cytosolic α -syn immunogold particles (arrows). When administered according to a chronic time-course protocol, Meth produces a robust increase in α -syn immunogold particles both in the nucleus and cytoplasm (arrows) of striatal cells at 24 h of withdrawal (panel B), which persists at 7 d and 21 d of withdrawal (panel C and D, respectively). The graph reports a quantification of Meth-induced increase of α -syn immunogold particles following a chronic protocol compared with Controls (saline-treated mice) (* p < 0.05 with respect to saline; ** p < 0.05 with respect to Meth withdrawal at 24 h and 7 d). N=nucleus; M=mitochondria. Scale bars A, B, C=200 nm; D=100 nm.

10. Meth produces a paradoxical increase striatal TH immunostaining that exceeds the amount of TH expressed in controls



CONCLUSION

- Meth produces a nigro-striatal toxicity and a paradoxical increase of TH immunoreactivity;
- Meth produces a persistently increase of alpha-synuclein immunoreactivity in sub-acute and chronic time-course protocols only;
- Meth increases alpha-synuclein protein levels and promotes hypomethylation of SNCA promoter in the sub-acute and chronic time-course protocol.